Akebia Ther is a drug manufacturers - specialty & generic business based in the US. Akebia Ther shares (AKBA) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $2.34 – a decrease of 3.7% over the previous week. Akebia Ther employs 181 staff and has a trailing 12-month revenue of around $160.2 million.
The Finder Score crunches 147 key metrics we collected directly from 18+ brokers and assessed each provider’s performance based on nine different categories, weighing each metric based on the expertise and insights of Finder’s investment experts. We then scored and ranked each provider to determine the best brokerage accounts.
We update our best picks as products change, disappear or emerge in the market. We also regularly review and revise our selections to ensure our best provider lists reflect the most competitive available.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $2.34 |
|---|---|
| 52-week range | $0.80 - $2.89 |
| 50-day moving average | $2.00 |
| 200-day moving average | $1.77 |
| Wall St. target price | $7.30 |
| PE ratio | N/A |
| Dividend yield | N/A |
| Earnings per share (TTM) | $-0.33 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $2.45 from 2025-05-02
| 1 week (2025-04-25) | 2.94% |
|---|---|
| 1 month (2025-04-04) | 38.42% |
| 3 months (2025-02-06) | 13.43% |
| 6 months (2024-11-06) | 22.50% |
| 1 year (2024-05-06) | 64.43% |
|---|---|
| 2 years (2023-05-04) | 163.50% |
| 3 years (2022-05-04) | 462.06% |
| 5 years (2020-05-05) | 11.95 |
| Revenue TTM | $160.2 million |
|---|---|
| Gross profit TTM | $134 million |
| Return on assets TTM | -12.49% |
| Return on equity TTM | -553.45% |
| Profit margin | -43.33% |
| Book value | $-0.22 |
| Market Capitalization | $640 million |
TTM: trailing 12 months
We're not expecting Akebia Ther to pay a dividend over the next 12 months.
Over the last 12 months, Akebia Ther's shares have ranged in value from as little as $0.8 up to $2.89. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Akebia Ther's is 0.864. This would suggest that Akebia Ther's shares are less volatile than average (for this exchange).
Akebia Therapeutics, Inc. , a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. Its product portfolio includes Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent (DD) and non-dialysis dependent (NDD) patients; and Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD and the treatment of iron deficiency anemia in adult patients with NDD-CKD. The company is also developing AKB-9090 for treating cardiac surgery-related acute kidney injury and acute respiratory distress syndrome; and AKB-10108 for the treatment of retinopathy of prematurity in neonates. The company has license and collaboration agreements with Mitsubishi Tanabe Pharma Corporation for the development and commercialization of Vafseo in Japan and other Asian countries. Akebia Therapeutics, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.
SoFi, Robinhood, Tastytrade, Webull, Interactive Brokers, E*TRADE, eToro and others top our list for the best options trading platforms.
See our picks for the best brokers for trading S&P 500 stocks, ETFs, options and futures.
Our picks of the best brokerage accounts for index funds for beginners, teens, proprietary funds and more.
These are the stocks to buy when you don’t have much to spend.
Cash sweep accounts let you earn interest on your uninvested cash. Learn how they work and how to choose the best one here.
eToro is a robust trading platform with an easy-to-use interface and no commissions on stocks and ETFs.
Check out our picks of the best trading apps for beginners, options traders, hands-off investors and more.
Thinking of switching from Moomoo? Here are 5 apps like Moomoo that offer valuable benefits
See our picks of the best brokerage accounts, including Fidelity, SoFi, Charles Schwab, Public, Robinhood and E*TRADE .
Webull is a broker with zero-commission trading and a suite of tools to help you invest.